Curated News
By: NewsRamp Editorial Staff
December 09, 2025
NeuroOne's Breakthrough Pain System Shows Success in Treating Facial Neuralgia
TLDR
- NeuroOne's FDA-cleared OneRF system offers surgeons a competitive edge with its multi-contact probe that reduces procedural time and improves precision in trigeminal neuralgia treatments.
- The OneRF system uses a multi-contact RF probe to deliver temperature-controlled energy, ablating trigeminal nerve fibers precisely without repositioning, minimizing complications in pain management procedures.
- This technology provides pain relief for chronic facial pain sufferers, improving quality of life for approximately 150,000 Americans annually and advancing neurological care options.
- NeuroOne's first pain management application successfully treated two patients with trigeminal neuralgia using thin film ablation technology originally developed for brain procedures.
Impact - Why it Matters
This development represents a significant advancement in treating chronic pain conditions that affect hundreds of thousands of patients who often struggle with limited treatment options. Trigeminal neuralgia causes excruciating facial pain that can be debilitating, and current treatments often involve medications with side effects or invasive surgeries with lengthy recovery times. NeuroOne's minimally invasive approach using temperature-controlled radiofrequency ablation could provide faster relief with fewer complications, potentially reducing healthcare costs and improving quality of life for patients. The technology's expansion into other pain management areas, particularly lower back pain which affects millions globally, suggests this could be the beginning of a broader transformation in how chronic pain is treated, moving toward more precise, targeted therapies with better safety profiles.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has achieved a significant milestone in pain management with its OneRF® Trigeminal Nerve Ablation System, successfully treating two patients suffering from trigeminal neuralgia at University Hospitals in Cleveland. The procedures, performed by Dr. Michael Staudt, Lincoln Endowed Chair in Brain Health, resulted in pain relief without postoperative complications, marking the company's first foray into pain management therapies using its patented thin film ablation technology. This development follows the Company's 510(k) clearance from the U.S. Food and Drug Administration in August 2025, which authorized marketing of the system for treating this chronic facial pain condition affecting approximately 150,000 Americans annually.
The OneRF® Trigeminal Nerve Ablation System represents a breakthrough in minimally invasive surgical technology, delivering targeted radiofrequency energy to ablate trigeminal nerve fibers and interrupt pain signaling. Its "first-of-its-kind" multi-contact RF probe allows surgeons to perform precise localization and targeted ablation using the same instrument without repositioning, potentially reducing procedural time while enhancing patient comfort and safety. Dr. Staudt praised the system's performance, noting it offers "meaningful advantages over other systems available today," while CEO Dave Rosa highlighted how this milestone validates NeuroOne's platform technology for both brain ablation and pain management applications.
Looking forward, NeuroOne plans to leverage its technology platform for additional pain management opportunities, including targeting the over $1 billion annual market for lower back pain treatment. The company's broader portfolio includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and the newly validated OneRF® Trigeminal Nerve Ablation System. These innovations aim to reduce hospitalizations, lower healthcare costs, and improve patient outcomes through combination diagnostic and therapeutic functions, positioning NeuroOne at the forefront of neurological disorder treatment advancements. For more information about the company's groundbreaking work, visit www.nmtc1.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne's Breakthrough Pain System Shows Success in Treating Facial Neuralgia
